Document Detail

Reactive oxygen species as therapeutic targets in pulmonary hypertension.
MedLine Citation:
PMID:  23328248     Owner:  NLM     Status:  Publisher    
Pulmonary hypertension (PH) is characterized by a progressive elevation of pulmonary arterial pressure due to alterations of both pulmonary vascular structure and function. This disease is rare but life-threatening, leading to the development of right heart failure. Current PH treatments, designed to target altered pulmonary vascular reactivity, include vasodilating prostanoids, phosphodiesterase-5 inhibitors and endothelin-1 receptor antagonists. Although managing to slow the progression of the disease, these molecules still do not cure PH. More effective treatments need to be developed, and novel therapeutic strategies, targeting in particular vascular remodelling, are currently under investigation. Reactive oxygen species (ROS) are important physiological messengers in vascular cells. In addition to atherosclerosis and other systemic vascular diseases, emerging evidence also support a role of ROS in PH pathogenesis. ROS production is increased in animal models of PH, associated with NADPH oxidases increased expression, in particular of several Nox enzymes thought to be the major source of ROS in the pulmonary vasculature. These increases have also been observed in vitro and in vivo in humans. Moreover, several studies have shown either the deleterious effect of agents promoting ROS generation on pulmonary vasculature or, conversely, the beneficial effect of antioxidant agents in animal models of PH. In these studies, ROS production has been directly linked to pulmonary vascular remodelling, endothelial dysfunction, altered vasoconstrictive responses, inflammation and modifications of the extracellular matrix, all important features of PH pathophysiology. Altogether, these findings indicate that ROS are interesting therapeutic targets in PH. Blockade of ROS-dependent signalling pathways, or disruption of sources of ROS in the pulmonary vasculature, targeting in particular Nox enzymes, represent promising new therapeutic strategies in this disease.
Véronique Freund-Michel; Christelle Guibert; Mathilde Dubois; Arnaud Courtois; Roger Marthan; Jean-Pierre Savineau; Bernard Muller
Related Documents :
16215348 - Amniotic fluid embolism.
23531298 - Pulmonary surfactant is indispensable in order to simulate the in vivo situation.
7954578 - Management of inferior pancreaticoduodenal artery aneurysms: a 4-year, single center ex...
24954988 - "open" approach to aortic arch aneurysm repair.
21307968 - Aortic valve replacement for stenosis with or without coronary artery bypass grafting a...
24099418 - Myelodysplastic syndrome with pulmonary tumor thrombotic microangiopathy in an 11-year-...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-17
Journal Detail:
Title:  Therapeutic advances in respiratory disease     Volume:  -     ISSN:  1753-4666     ISO Abbreviation:  Ther Adv Respir Dis     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-18     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101316317     Medline TA:  Ther Adv Respir Dis     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Pharmaceutiques, Université Bordeaux Segalen, Bordeaux Cedex, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Current Recommendations for Cervical Cancer Screening: Do They Render the Annual Pelvic Examination ...
Next Document:  Meta-Analysis of MMP9 -1562C/T and the Risk of Coronary Heart Disease.